Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 7:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 458 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: higher sodium Clear all
Terminated Phase 1Phase 2 Interventional Results available

Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Type I

NCT00439218
View directory record Official record
Conditions
Spinal Muscular Atrophy Type I
Interventions
sodium phenylbutyrate
Drug
Lead sponsor
Westat
Other
Eligibility
2 Months to 48 Months
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Stanford, California • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2010 · Synced Sep 1, 2026, 7:52 PM EDT
Completed Not applicable Interventional Results available

Aldosterone and Glucose Homeostasis

NCT00732160
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Aldosterone infusion (A), Vehicle Infusion (V), High Sodium Diet (HS), Low Sodium Diet (LS)
Drug · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Sep 1, 2026, 7:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess Effects of Age, Weight, and Body Composition on the Pharmacokinetics of IV Diclofenac Sodium

NCT00509743
View directory record Official record
Conditions
Healthy
Interventions
Intravenous diclofenac sodium (DIC075V)
Drug
Lead sponsor
Javelin Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Miramar, Florida • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 11, 2009 · Synced Sep 1, 2026, 7:52 PM EDT
Recruiting Phase 2 Interventional

A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures

NCT05610085
View directory record Official record
Conditions
Neonatal Seizure, Neonatal Encephalopathy, Hypoxic-Ischemic Encephalopathy, Seizure Newborn
Interventions
Levetiracetam Injection, Phenobarbital Sodium Injection
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
Up to 1 Month
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
San Diego, California • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 1, 2026, 7:52 PM EDT
Completed Phase 2 Interventional Results available

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

NCT00787761
View directory record Official record
Conditions
Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT
Biological · Drug · Procedure
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
Up to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 30, 2012 · Synced Sep 1, 2026, 7:52 PM EDT
Completed Phase 2 Interventional Results available

Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation

NCT03434730
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Myelodysplastic-Myeloproliferative Diseases, Myeloproliferative Disorder, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Leukemia
Interventions
Total Body Irradiation, Cyclosporine, Mycophenolate Mofetil, Tocilizumab, Filgrastim
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 1, 2026, 7:52 PM EDT
Completed Phase 4 Interventional

Arterial pH and Total Body Nitrogen Balances in APD

NCT00586131
View directory record Official record
Conditions
End-stage Renal Disease
Interventions
ammonium chloride or sodium citrate/citric acid, Sodium citrate/citratic acid
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2017 · Synced Sep 1, 2026, 7:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study of Detergents in the Pathogenesis of Eosinophilic Esophagitis

NCT05482256
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Esophageal String Test (EST), Colgate, High Resolution Esophageal Manometry (HREM)
Diagnostic Test · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Sep 1, 2026, 7:52 PM EDT
Terminated Phase 2 Interventional

A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease

NCT04428775
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
ALZT-OP1a (cromolyn)
Drug
Lead sponsor
AZTherapies, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
6
States / cities
La Jolla, California • Jacksonville, Florida • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2021 · Synced Sep 1, 2026, 7:52 PM EDT
Withdrawn Phase 2 Interventional

Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma

NCT03719560
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma
Interventions
Methotrexate, Cytarabine
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 12, 2020 · Synced Sep 1, 2026, 7:52 PM EDT
Completed Not applicable Interventional Results available

Trial of Dialysate Sodium in Chronic Hospitalized Hemodialysis Patients

NCT02145260
View directory record Official record
Conditions
Intra-dialytic Hypotension
Interventions
Lower dialysate sodium (138 mmol/L; using Renasol hemodialysis concentrate), Higher dialysate sodium (142 mmol/L; using Renasol hemodialysis concentrate)
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 30, 2022 · Synced Sep 1, 2026, 7:52 PM EDT
Completed Phase 2 Interventional

C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma

NCT01530269
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
C11-Sodium Acetate
Drug
Lead sponsor
Phoenix Molecular Imaging
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Sep 1, 2026, 7:52 PM EDT
Completed Phase 2 Interventional Results available

Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma

NCT00879437
View directory record Official record
Conditions
Glial Cell Tumors, Malignant Gliomas, Glioblastoma Multiforme, Anaplastic Astrocytoma, Gliomatosis Cerebri, Gliosarcoma, Brainstem Glioma, Diffuse Intrinsic Pontine Glioma
Interventions
Valproic acid, Bevacizumab, Radiation therapy
Drug · Radiation
Lead sponsor
Baylor College of Medicine
Other
Eligibility
3 Years to 21 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
6
States / cities
Oklahoma City, Oklahoma • Dallas, Texas • Fort Worth, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Sep 1, 2026, 7:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

FFA-Induced Hypertension and Endothelial Dysfunction

NCT00589888
View directory record Official record
Conditions
Endothelial Dysfunction, Hypertension
Interventions
Intralipid 20% @ 20cc/hour, Intralipid 20%@ 40cc/hour, Normal Saline, 32-gram oral fat load, 64-gram oral fat load
Drug · Dietary Supplement
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Sep 1, 2026, 7:52 PM EDT
Completed Phase 3 Interventional Results available

Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol

NCT03399370
View directory record Official record
Conditions
ASCVD, Elevated Cholesterol
Interventions
Inclisiran Sodium, Placebo
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
1,561 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
145
States / cities
Birmingham, Alabama • Foley, Alabama • Huntsville, Alabama + 110 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Sep 1, 2026, 7:52 PM EDT
Completed Phase 3 Interventional Results available

Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI

NCT02924727
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
LCZ696 (sacubitril/valsartan), Ramipril, Placebo of LCZ696, Placebo of ramipril, Valsartan, Placebo of valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
5,669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
81
States / cities
Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 1, 2026, 7:52 PM EDT
Terminated Phase 4 Interventional

Trial Comparing Three Single Dose Injections for Knee Osteoarthritis

NCT05492851
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Zilretta, Synvisc-One 48 MG in 6 ML Prefilled Syringe, Monovisc 88 MG Per 4 ML Prefilled Syringe
Drug
Lead sponsor
Ohio State University
Other
Eligibility
25 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Columbus, Ohio • Lewis Center, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 9, 2023 · Synced Sep 1, 2026, 7:52 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

3M Oral Rinse Incidence and Patient Acceptance of Sloughing When Used With Sodium Lauryl Sulfate (SLS) Toothpastes

NCT04601103
View directory record Official record
Conditions
Oral Mucosal Disorder
Interventions
No SLS toothpaste, Medium SLS toothpaste, High SLS toothpaste, Anti-plaque
Drug · Device
Lead sponsor
Solventum US LLC
Industry
Eligibility
18 Years to 90 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Sep 1, 2026, 7:52 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Rhu-pGSN to Mitigate Proinflammatory Responses to Decompression in Healthy SCUBA Divers

NCT06216366
View directory record Official record
Conditions
Decompression Sickness
Interventions
Sodium Chloride 0.9% Inj pre-exposure, Sodium Chloride 0.9% Inj post-exposure, Recombinant human plasma gelsolin pre-exposure, Recombinant human plasma gelsolin post-exposure, Hyperbaric chamber
Drug · Other
Lead sponsor
BioAegis Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Sep 1, 2026, 7:52 PM EDT
Completed No phase listed Observational

A Biomarker to Detect Salt Sensitivity

NCT03147170
View directory record Official record
Conditions
Hypertension Uncomplicated, Pre Hypertension
Interventions
High and low salt diets
Diagnostic Test
Lead sponsor
University of Minnesota
Other
Eligibility
30 Years to 75 Years
Enrollment
30 participants
Timeline
2016 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Sep 1, 2026, 7:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate VH4524184 Tablet Absorption, Effects of Food, and Interactions With Other Drugs in Healthy Adults

NCT07066722
View directory record Official record
Conditions
HIV Infections
Interventions
VH4524184, Itraconazole, Rifabutin, Phenytoin, Metformin, Digoxin
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 60 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Lenexa, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 1, 2026, 7:52 PM EDT
Terminated Phase 1 Interventional

Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT02277184
View directory record Official record
Conditions
Carcinoma, Squamous Cell of Head and Neck
Interventions
Ficlatuzumab, Cisplatin, Intensity Modulated Radiotherapy (IMRT)
Drug · Radiation
Lead sponsor
Julie E. Bauman, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 12, 2017 · Synced Sep 1, 2026, 7:52 PM EDT
Completed Not applicable Interventional Results available

MOBILE Intervention in College Students With Elevated Blood Pressure

NCT05956925
View directory record Official record
Conditions
Hypertension
Interventions
Intervention group was asked to take their BP daily and rate their motivation level and communicate with the research assistant. Their level will trigger the appropriate behavioral change SMS prompt.
Behavioral
Lead sponsor
University of Nevada, Las Vegas
Other
Eligibility
18 Years to 29 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Sep 1, 2026, 7:52 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients

NCT00251004
View directory record Official record
Conditions
Kidney Transplantation, Graft Rejection
Interventions
Everolimus, Mycophenolic Acid (MPA), Cyclosporine A (CsA), Basiliximab, Corticosteroids
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
833 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 9, 2011 · Synced Sep 1, 2026, 7:52 PM EDT